Decision to list medical devices supplied by LifeHealthcare Limited and Surgical Innovations Limited
We are pleased to announce the approval of non-exclusive listing agreements with LifeHealthcare Limited and Surgical Innovations Limited for the supply of orthopaedic implants and associated products.
In summary, this will result in LifeHealthcare and Surgical Innovations ranges of Orthopaedic Products being listed in Part III of Section H of the Pharmaceutical Schedule from 1 April 2020.
DHBs will be able to continue to purchase other suppliers’ brands of Orthopaedic Products as the agreements are not for sole supply.
Any changes to the original proposal?
This decision was subject to the following consultation letters:
No changes have been made to either agreement as a result of consultation.
Who we think will be most interested
- Suppliers and Wholesalers
- DHB Staff:
- Orthopaedic surgeons
- Perioperative personnel
- Sterile services personnel
- Procurement and supply chain personnel
Detail about this decision
In April 2016 PHARMAC issued a request for proposals (“RFP”) for orthopaedic implants and associated products. The RFP requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
After evaluating LifeHealthcare’s and Surgical Innovation’s proposals and consulting on the provisional agreements reached with them, PHARMAC has decided to list LifeHealthcare’s and Surgical Innovation’s ranges of Orthopaedic Products in Part III of Section H of the Pharmaceutical Schedule from 1 April 2020.
These two agreements are the final agreements that will be entered into in the orthopaedic products category as a result of the RFP.
The following product ranges and brands are included in the agreements:
Anterior Spine Truss,Cervical Spine Truss, Posterior Spine Truss
Distal joint and Trauma implants
Surgical bone cements and Allografts
Our response to what you told us
We appreciate the time people took to respond to this consultation.
All consultation responses received by 13 February 2020 and 25 February 2020, respectively, were considered in their entirety in making the decision to approve each agreement.
A summary of the main themes raised in feedback and our responses to the feedback are set out below:
|LifeHealthcare and Surgical Innovations
|No technical or resource impacts are exected as a result of the proposals
|Savings opportunity noted
If you have any questions about this decision, you can email us at firstname.lastname@example.org; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.